SeaStar Medical's Selective Cytopheretic Device for cardiorenal syndrome receives US FDA Breakthrough Device Designation

  • Kevin Chung

Press/Media

Period3 Oct 2023

Media coverage

1

Media coverage

  • TitleSeaStar Medical's Selective Cytopheretic Device for cardiorenal syndrome receives US FDA Breakthrough Device Designation
    Media name/outletPharmaBiz
    Country/TerritoryIndia
    Date3/10/23
    PersonsKevin Chung
View all 1
View less